Pacira BioSciences
PCRX
177 hedge funds and large institutions have $1.76B invested in Pacira BioSciences in 2015 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 76 increasing their positions, 48 reducing their positions, and 41 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 48
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
3% less call options, than puts
Call options by funds: $9.23M | Put options by funds: $9.48M
5% less funds holding
Funds holding: 187 → 177 (-10)
20% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 41
42% less capital invested
Capital invested by funds: $3.03B → $1.76B (-$1.27B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$143M |
| 2 |
DM
Deerfield Management
New York
|
+$30M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$23.3M |
| 4 |
DCM
Daruma Capital Management
New York
|
+$22.9M |
| 5 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$146M |
| 2 |
Jennison Associates
New York
|
-$44M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$39.6M |
| 4 |
SFM
Soros Fund Management
New York
|
-$37.6M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$37.1M |
PCRX Hedge Fund Activity: Q3 2015 in Review
177 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2015, worth a combined $1.76B — down 42% from $3.03B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of PCRX and 33 opened new positions — a net loss of 8 holders — while 48 trimmed existing stakes and 76 added.
The largest buyer was Visium Asset Management, adding an estimated $143M. The largest seller was Janus Henderson Investors US, cutting an estimated $146M.
- 177 institutional investors held Pacira BioSciences (PCRX) as of Q3 2015, down from 187 in Q2 2015.
- Funds reported $1.76B of Pacira BioSciences stock for Q3 2015, down 42% quarter-over-quarter.
- 33 funds opened new Pacira BioSciences positions in Q3 2015 and 41 closed out, a net change of -8 holders.
- The largest Pacira BioSciences buyer in Q3 2015 was Visium Asset Management, an estimated $143M added.
- The largest Pacira BioSciences seller in Q3 2015 was Janus Henderson Investors US, an estimated $146M sold.
Based on aggregated 13F filings for Q3 2015.